José Ramón
González Porras
Profesor Asociado CC. Salud
Hospital Universitario La Paz
Madrid, EspañaHospital Universitario La Paz-ko ikertzaileekin lankidetzan egindako argitalpenak (21)
2022
-
Clinical Efficacy and Safety of Fanhdi®, a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, Vol. 28
-
Novel Therapies to Address Unmet Needs in ITP
Pharmaceuticals, Vol. 15, Núm. 7
2021
-
A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients
Blood Cells, Molecules, and Diseases, Vol. 86
-
Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (Scientific Reports, (2019), 9, 1, (16680), 10.1038/s41598-019-53209-y)
Scientific Reports
-
Elucidating the mechanism of action of the attributed immunomodulatory role of eltrombopag in primary immune thrombocytopenia: An in silico approach
International Journal of Molecular Sciences, Vol. 22, Núm. 13
2019
-
Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations
Revista Espanola de Cardiologia, Vol. 72, Núm. 9, pp. 749-759
-
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia
Scientific Reports, Vol. 9, Núm. 1
-
Management of adult patients with primary immune thrombocytopenia (itp) in clinical practice: A consensus approach of the Spanish itp expert group
Advances in Hematology, Vol. 2019
2017
-
Application of a molecular diagnostic algorithm for haemophilia A and B using next-generation sequencing of entire F8, F9 and VWF genes
Thrombosis and Haemostasis, Vol. 117, Núm. 1, pp. 66-74
-
Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice
International Journal of Hematology, Vol. 106, Núm. 4, pp. 508-516
-
Use of eltrombopag for secondary immune thrombocytopenia in clinical practice
British Journal of Haematology, Vol. 178, Núm. 6, pp. 959-970
2016
-
Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice
European Journal of Haematology, Vol. 97, Núm. 3, pp. 297-302
-
Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines
Annals of Hematology, Vol. 95, Núm. 7, pp. 1089-1098
2015
-
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia
Annals of Hematology, Vol. 94, Núm. 6, pp. 911-918
-
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia
American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43
-
Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia
Platelets, Vol. 26, Núm. 1, pp. 83-86
-
Use of eltrombopag after romiplostim in primary immune thrombocytopenia
British Journal of Haematology, Vol. 169, Núm. 1, pp. 111-116
2012
-
Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome
Cancer, Vol. 118, Núm. 1, pp. 127-133
-
The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome
Leukemia Research, Vol. 36, Núm. 3, pp. 287-292
2011
-
Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome
Cancer, Vol. 117, Núm. 24, pp. 5529-5537